# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
MariMed (OTC:MRMD) reported quarterly sales of $37.933 million which beat the analyst consensus estimate of $36.950 million by ...
the U.S. Drug Enforcement Administration (DEA) is reportedly moving cannabis from Schedule I to Schedule III